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Surgery  has  been  long  considered  to  be the treatment  of  choice  for glomus  jugulare  paragangliomas,  as
it is  the  only  modality  able  to totally  eradicate  the  tumour.  However,  despite  considerable  progress  in
interventional  radiology  and  nerve  monitoring,  surgery  is  associated  with  an  unacceptably  high  com-
plication  rate  for a benign  tumour,  explaining  the growing  place  of  radiotherapy  in the management
of  these  tumours.  This  review  of  the literature  conﬁrms  the  efﬁcacy  of  conformal  radiotherapy  with  or
without  intensity  modulation  and  stereotactic  radiotherapy,  which  both  achieve  tumour  control  rates
ranging  from  90%  to  almost  100%  of  cases,  but for different  tumour  volumes,  almost  constant  stabilization
or  even  improvement  of symptoms,  and a  considerably  lower  rate  of adverse  effects  than  with  surgery.
However,  radiotherapy  remains  contraindicated  in  the  presence  of intracranial  invasion  or extensive
osteomyelitis.  In the  light  of these  results,  together  with  the  improved  quality  of life and  a better  knowl-
edge  of the natural  history  of  this  disease,  many  authors  propose  radiotherapy  as  ﬁrst-line  treatment  for
all glomus  jugulare  paragangliomas  regardless  of  their  size,  particularly  in  patients  with  no  preoperative
deﬁcits.
©  2014  Published  by Elsevier  Masson  SAS.For a long time, radiotherapy was the only treatment option
vailable to otorhinolaryngologists to try to control glomus jugu-
are paragangliomas [1,2]. The complex anatomy of the region
nd the limited surgical techniques available discouraged a more
azardous approach, especially surgical resection of this highly
aemorrhagic tumour [3,4].
However, from the 1980s onwards, the development of
icrosurgical techniques combined with progress in morpholog-
cal interventional radiology and electrophysiological monitoring
llowed surgical resection preceded by embolization to become the
reatment of choice [5].
Nevertheless, the surgical iatrogenic effects frequently
bserved, which are increasingly unacceptable for a benign
umour, the growing importance of quality of life, the better
nowledge of the natural history of the tumour and improve-
ent of techniques and introduction of new irradiation modalities
xplain why radiotherapy now, once again, constitutes an essential
reatment option [6,7].
This article presents a review of the literature concerning the
urrent place of radiotherapy in the management of glomus jugu-
are paraganglioma.E-mail address: patrice.tran-ba-huy@lrb.aphp.fr
http://dx.doi.org/10.1016/j.anorl.2014.01.003
879-7296/© 2014 Published by Elsevier Masson SAS.1. Various radiotherapy modalities
1.1. Conventional external beam radiotherapy
Conventional external beam radiotherapy delivering photons
emitted by Cobalt 60 at doses of 45–55 Gy in 20–25 sessions con-
stituted the reference modality for a long time. However, it is
associated with a risk of certain complications, such as temporal
osteoradionecrosis, cranial nerve palsy, or even second tumour. It
has now been replaced by two other techniques [8,9].
1.2. Conformal radiotherapy with or without intensity
modulation
Initially two-dimensional irradiation (based on standard radio-
graphy) has become three-dimensional or conformal. By basing
irradiation ﬁelds on CT and MRI  data, conformal radiotherapy
allows the intensity of the irradiation delivered to be adapted to
the shape and size of the tumour.
Intensity-modulated conformal radiotherapy (IMRT) was
introduced in 1995, allowing intensity of irradiation to be adapted
to the shape and size of the tumour by means of mobile multi-leaf
collimators. As a result of precise tumour delineation, irradiation is
modulated in terms of time and dose: high dose to the tumour (2
to 2.2 Gy/session), lower doses to tumour margins (1.6 Gy/session),
and theoretically very low doses to healthy tissues.
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The conformation and homogeneity of the doses delivered by
MRT are further improved by tomotherapy: a medium-energy
ccelerator is connected to the CT scan gantry and revolves around
he table, which is displaced longitudinally. Helical irradiation is
herefore adapted to the target volume in real time.
.2.1. Recommended doses
The dose necessary and sufﬁcient to control this slowly growing,
enign tumour appears between 40 and 50 Gy [10,11] adminis-
ered in 25 fractions, 5 days a week, for an average of 35 days. This
ose avoids toxic effects, especially temporal necrosis and osteora-
ionecrosis, while ensuring satisfactory local control (see below).
his dose schedule therefore constitutes an efﬁcacy-safety com-
romise: relapses are observed at doses less than 40 Gy [12], while
t doses higher than 50 Gy, the relapse rate is not lower than that
bserved at radiation doses between 40 and 50 Gy.
.3. Stereotactic radiotherapy
.3.1. Principle
Stereotactic radiotherapy consists of delivering radiation by
sing mini-beams converging onto the tumour target. In practice,
hotons are delivered to the tumour precisely delineated by CT
nd MRI  image fusion [13]. Stereotactic radiotherapy therefore only
rradiates the tumour volume and stops its biological activity. The
ose delivered, initially about 50 Gy, has now been decreased to
2–14 Gy to avoid damage to adjacent tissues. This dose is delivered
n a single session. However, recent studies suggest the advantages
f dose fractionation [14]. Precision at the target is about 0.25 mm
nd this modality appears to be very effective on the tumour blood
upply.
.3.2. Types of equipment
Three types of equipment can be used:
Gamma  Unit or Gamma  Knife uses gamma  radiation of photons
emitted from the nucleus of the Cobalt 60 atom and projected
by a comb-line arrangement of 201 sources distributed in 5
crowns around a steel hemisphere inside a primary collimator
that directs the radiation to the centre. A rigid metallic frame is
ﬁxed to the patient’s head under local anaesthesia to prevent any
head movements. Treatment lasts 30 to 90 minutes;
the LINAC is a linear particle accelerator producing X photons
used according to kinetic radiotherapy. This conformal radio-
therapy adapts the irradiated volume to the tumour volume by
modulating the direction of the beams and by means of a multi-
leaf collimator that modulates the dose rate delivered by each
beam;
the CyberKnife® is a miniaturized version of the LINAC attached
to an industrial robot with 6 axes of mobility. Combining highly
ﬂexible targeting and beam orientation, it can be used to detect,
track and correct real time displacements of the tumour and
the patient’s movements during treatment with an accuracy of
less than one millimetre. In contrast with the Gamma  Knife, the
CyberKnife system does not use a stereotactic frame but two X-
ray cameras.
The radiation source can therefore be either single (LINAC
r Cyberknife) or multiple (Gamma  knife), with either single
Gamma  knife or LINAC) or fractionated dose delivery (LINAC and
yberknife).
.3.3. Advantages and limitations
The advantages of stereotactic radiotherapy are:gy, Head and Neck diseases 131 (2014) 223–226
• sparing of healthy tissues by means of perfect conformation of
the radiation onto a well deﬁned target, stabilized by a speciﬁc
contention system;
• it can be used after failure of normofractionated radiotherapy;
• the patient is immobilized for only one session and therefore only
1- to 2-day hospitalisation is required.
The patient can therefore rapidly return home and can return to
work the following week. In terms of economic impact (duration of
immobilization, hospital expenses, sick leave, etc.), this technique
is also 25 to 30% less expensive than a neurosurgical procedure [15].
Its limitations are:
• it can only be used to irradiate a small tumour volume and is
therefore reserved for small paragangliomas;
• it can only be applied to intracranial paragangliomas, i.e. arising
in a region that can be easily repositioned from one session to
the next and which can be immobilized, although the Cyberknife
overcomes this limitation.
2. Tumour control
The efﬁcacy of radiotherapy is deﬁned not by disappearance of
the tumour, but by tumour control, i.e. stabilization and absence
of recurrence of symptoms and absence of tumour growth and
radiological signs of progression [16]. This deﬁnition is now widely
accepted and the published results all appear to be concordant,
regardless of the technique used.
2.1. Conventional radiotherapy
All studies published since the 1970s have reported tumour con-
trol rates close to 90% [12,16–25]. In his doctorate thesis, Dupin
reported a 5-year local control rate of 97% and a 10-year local
control rate of 94%, i.e. better results than those obtained with
surgery [24]. He also suggested that advanced age and large tumour
volume appeared to constitute risk factors for failure of radio-
therapy, in which case the tumour could be treated by salvage
surgery.
2.2. Stereotactic radiotherapy
Most recent data of the literature show that Gamma  Knife, LINAC
and/or Cyberknife achieve very good tumour and symptom control
rates, ranging from 71% to 100% and 88% to 100%, respectively, with
much lower morbidity than with surgery [26–33]. Several tran-
sient adverse effects have been reported, such as facial paralysis
and headache. In contrast, pulsatile tinnitus and deafness generally
remain unchanged. However, this stereotactic irradiation modality
only concerns residual paragangliomas less than 3 cm in diame-
ter or that have relapsed after surgery. Fractionated irradiation
delivering low doses in 30 sessions equivalent to a single dose of
15–16 Gy also appears to be an interesting option for inoperable
giant paraganglioma [14].
3. Functional results
Functional results are difﬁcult to assess in view of the wide range
of symptoms and the heterogeneous methodologies of the stud-
ies evaluating these results. However, regression of signs of nerve
paralysis (dysphonia, swallowing disorders or even facial paralysis)
are observed in about 20% of cases.
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. Adverse effects
The introduction of intensity-modulated conformal radiothe-
apy (IMRT) that adapts the intensity delivered to the shape and size
f the tumour has markedly decreased iatrogenic effects [22,26]
ithout affecting tumour control rates in practically all series pub-
ished to date.
Acute toxicity symptoms are frequently observed, such as nau-
ea, weight loss or mucositis, which may  require interruption of
reatment or even hospitalisation [24].
Long-term adverse effects are dominated by xerostomia with
ysphagia, ear problems such as serous otitis media or exter-
al otitis and stenosis of the external auditory canal, and more
arely neurological disorders such as headache, ageusia or transient
lossopharyngeal, vagus, and accessory nerve paralysis with swal-
owing disorders, aspiration or dysphonia. Other complications are
ery rare: temporal osteoradionecrosis, cerebral radiation necrosis
r vascular disorders such as labile blood pressure or, more serious,
arotid artery stenosis with resolving or permanent hemiplegia.
Paradoxically, stereotactic radiotherapy is responsible for more
evere neurological toxicity than conventional normofractionated
adiotherapy, as delivery of stereotactic radiotherapy as a single
ose results in a dose equivalent to 15 Gy, or even 35 Gy on the
0% isodose [16] versus about 2 Gy per session for conventional
ormofractionated radiotherapy.
The risk of radiation-induced cancer, either malignant transfor-
ation of the residual tumour occurring years later or malignant
ransformation of irradiated healthy tissues, appears to be very low,
anging from 0.28% [34] to 1/2000 [35]. Several cases of ﬁbrosar-
oma [35], malignant astrocytoma or glioma [36], and meningioma
24] have been reported in the literature. This risk must be weighed
p against the much higher risk of neurological lesions and com-
lications secondary to tumour progression.
. Implications for the indications of radiotherapy
This review of the literature therefore appears to demonstrate
hat ﬁrst-line radiotherapy provides better results than those of
urgery, regardless of the tumour volume:
all published series report tumour control rates of up to 95 to
100% for follow-ups that are now up to ten years;
in terms of functional results, radiotherapy appears to stabilize
or even improve neurological lesions and induces few iatrogenic
effects, and certainly far fewer iatrogenic effects than surgery
[6,37–39].
Hearing and facial nerve functions are usually preserved after
reatment, especially since reduction of the doses are delivered.
These ﬁndings suggest the need to redeﬁne the place of radio-
herapy, which is classically indicated in three main situations:
exclusive radiotherapy for inoperable tumours due to tumour
size, internal carotid artery invasion with poorly tolerated clam-
ping test or exclusively ipsilateral venous return or deﬁcient
contralateral venous return – various types of surgical contraindi-
cations – or bilateral tumours;
as an adjunct to incomplete surgery;
salvage therapy after failure of surgery or relapse.
The published results together with the improved quality of life
nd a better knowledge of the natural history of the disease suggest
hat radiotherapy can be proposed as ﬁrst-line treatment for all glo-
us  jugulare paragangliomas regardless of their size, particularly
n patients with no preoperative deﬁcit.gy, Head and Neck diseases 131 (2014) 223–226 225
Surgery remains indicated in certain situations: young patients;
preoperative facial nerve or glossopharyngeal, vagus, and acces-
sory nerve paralysis; low probability of surgical complications;
intracranial extension; recurrence after irradiation; major petro-
clival extension with internal carotid artery invasion and well
tolerated clamping test. An emerging concept, which used to be sac-
rilegious but which is now recommended by many authors, is that
of subtotal or almost-total resection leaving residual tumour in con-
tact with critical nerves or blood vessels and systematic adjuvant
radiotherapy or when radiological follow-up suggests growth of
the residual tumour. Another argument justifying ﬁrst-line surgery
can be that resection of surrounding bone reduces the risk of late
osteoradionecrosis in the event of subsequent radiotherapy.
6. Special indications: malignant and/or secreting forms
The place of radiotherapy is not clearly deﬁned in this particular
setting.
Surgical resection is theoretically the only curative treatment for
primary and secondary malignant paragangliomas. However, the
treatment options for these tumours depend on their site and their
operability. Surgery is obviously indicated in the case of isolated or
multiple cervical, thoracic or abdominal lymph node metastases,
especially as it allows histological conﬁrmation of malignancy.
Similarly, a solitary liver metastasis may  be amenable to surgical
resection. Complete surgical resection allows long-term survival
[40–43].
However, two-thirds of metastases are situated in bone, usu-
ally the vertebrae, and are therefore unresectable. Decompression
laminectomy followed by vertebroplasty can be proposed in the
presence of signs of spinal cord compression. Combined medi-
cal and surgical treatment can also be proposed: analgesics and
anti-inﬂammatory drugs to control pain and nerve compression
phenomena, as well as biphosphonates and localized radiotherapy
or sometimes embolization and radiofrequency ablation.
Surgery of secreting tumours is always very delicate and must
be preceded and accompanied by very careful medical prepara-
tion [44–46]. Surgical dissection must comprise control of feeding
arteries and every effort must be taken to avoid capsular effraction.
Many authors consider radiotherapy to be a particularly valuable
alternative.
7. Conclusions and perspectives
This review of the literature appears to demonstrate that radio-
therapy now constitutes an effective treatment for glomus jugulare
paragangliomas with an equivalent if not better tumour control
rate and considerably fewer iatrogenic effects than surgery. The
management of glomus jugulare paraganglioma therefore closely
follows the changing approach to the management of acoustic neu-
roma.
However, the potential late toxicity of radiotherapy suggests
that treatment will inevitably evolve towards chemotherapy.
Tenenbaum et al. [47], using cold (non-radioactive) octreotide,
demonstrated a 50% reduction of the size of a parotid metastasis
of paraganglioma, and Kau and Arnold [48] reported 22% and 47%
reductions of tumour size, respectively, after 6 months of treat-
ment in 2 patients. Metabolic scintigraphy or chemotherapy can
raise objections related to their cost, the low tumour growth rate
and their adverse effects [49]. The future will therefore proba-
bly consist of targeted molecular treatments designed to inhibit
genes targeted by hypoxia-induced factors. Ongoing trials in the
treatment of malignant paraganglioma may  provide a positive
response to the hopes for purely medical management of this dis-
ease [50].
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